BMJ investigation raises new concerns over ticagrelor approval trials
Multibilian dollars in a follow -up investigation in drug Tikgralor, BMJ Fresh concerns have been exposed, this time in major platelet studies used in its FDA approval. For more than a decade, Ticagrelor (Brillinta in the US and brillic in Europe) have been recommended for patients with acute coronary syndrome – a series of conditions […]
